[Retracted] Implications of Human Antimicrobial Peptide Defensin Beta-1 in Clinical Oral Squamous Cell Carcinoma Patients via an Integrated Bioinformatics Approach
Table 3
Logistic regression analysis results showing the association between DEFB1 expression and clinical characteristics.
Characteristics
Total ()
Odds ratio (OR) (95% confidence interval (CI))
value
T stage (T3 & T4 vs. T1 & T2)
319
1.072 (0.682-1.684)
0.764
N stage (N1 & N2 & N3 vs. N0)
315
0.706 (0.452-1.100)
0.125
M stage (M1 vs. M0)
312
1.013 (0.040-25.769)
0.993
Clinical stage (Stage III & Stage IV vs. Stage I & Stage II)
319
0.876 (0.537-1.427)
0.594
Histologic grade (G3 & G4 vs. G1 & G2)
321
0.812 (0.474-1.383)
0.443
Gender (male vs. female)
329
0.900 (0.563-1.437)
0.660
Race (Asian & Black or African American vs. White)
318
1.143 (0.537-2.457)
0.728
Age (>60 vs. ≤60)
328
1.215 (0.787-1.877)
0.380
Smoker (yes vs. no)
323
0.977 (0.597-1.599)
0.927
Alcohol history (yes vs. no)
321
0.532 (0.329-0.853)
0.009
Primary therapy outcome (PD & SD vs. PR & CR)
278
1.135 (0.575-2.247)
0.714
Radiation therapy (no vs. yes)
295
0.923 (0.578-1.473)
0.737
Lymph node neck dissection (no vs. yes)
327
0.558 (0.287-1.054)
0.076
Lymphovascular invasion (yes vs. no)
239
0.950 (0.549-1.643)
0.855
Anatomic neoplasm subdivision (oral cavity & hard palate & floor of mouth & buccal mucosa & base of tongue & alveolar ridge vs. oral tongue)
